These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35598360)

  • 1. Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening.
    Delaye M; Ibadioune S; Julié C; Marin C; Peschaud F; Lupinacci R; Vacher S; Ahmanache L; Antonio S; Schnitzler A; Buecher B; Mariani P; Allory Y; Grati OT; Emile JF; Neuzillet C; Bièche I
    Eur J Cancer; 2022 Jul; 170():85-90. PubMed ID: 35598360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
    Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
    Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.
    Vaňková B; Vaněček T; Ptáková N; Hájková V; Dušek M; Michal M; Švajdler P; Daum O; Daumová M; Michal M; Mezencev R; Švajdler M
    Genes Chromosomes Cancer; 2020 Oct; 59(10):562-568. PubMed ID: 32427409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
    Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
    J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Martianov AS; Mitiushkina NV; Ershova AN; Martynenko DE; Bubnov MG; Amankwah P; Yanus GA; Aleksakhina SN; Tiurin VI; Venina AR; Anuskina AA; Gorgul YA; Shestakova AD; Maidin MA; Belyaev AM; Baboshkina LS; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
    Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological and molecular evaluation of BRAF, KRAS, NRAS genes and MSI in the development of colorectal cancer.
    Paula Simedan Vila A; Helena Rodrigues G; Leite Marzochi L; Garcia de Oliveira-Cucolo J; Lívia Silva Galbiatti-Dias A; Felipe Maciel Andrade R; de Santi Neto D; Gomes Netinho J; Castiglioni L; Cristina Pavarino É; Maria Goloni-Bertollo E
    Gene; 2023 Jun; 870():147395. PubMed ID: 36990254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
    Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
    BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
    Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
    Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
    Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.
    Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K
    Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy.
    Yamane LS; Scapulatempo-Neto C; Alvarenga L; Oliveira CZ; Berardinelli GN; Almodova E; Cunha TR; Fava G; Colaiacovo W; Melani A; Fregnani JH; Reis RM; Guimarães DP
    Oncol Rep; 2014 Oct; 32(4):1419-26. PubMed ID: 25050586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.